The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive of reduced TTFT (P < .001) and overall survival (P = .002). Multivariate analysis confirmed that high Ang2 was an independent prognosticator for TTFT (hazard ratio = 1.739; 95% confidence interval, 1.059-2.857; P = .029). Significant associations were found between high Ang2 and advanced Binet stages (P < .001), high beta(2)-microglobulin (P < .001), unmutated variable region of immunoglobulin heavy chain gene status (P < .001), high CD38 and zeta-chain-associated protein kinase 70 expression (P < .001 and P = .003), and intermediate/high cytogenetic risk (P = .005). Moreover, Ang2 added prognostic power to other conventional prognosticators and helped to refine prognosis among CLL subsets with both high and low vascular endothelial growth factor plasma levels. Ang2 plasma level may be a useful independent prognosticator for CLL.

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia / Maffei, Rossana; Martinelli, Silvia; Santachiara, R; Rossi, D; Guarnotta, C; Sozzi, E; Zucchetto, A; Rigolin, Gm; Fiorcari, Stefania; Castelli, Ilaria; Fontana, M; Coluccio, Valeria; Leonardi, G; Zucchini, P; Tripodo, C; Cuneo, A; Gattei, V; Del Poeta, G; Forconi, F; Gaidano, G; Torelli, Giuseppe; Marasca, Roberto. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 116:(2010), pp. 584-592. [10.1182/blood-2009-11-252494]

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

MAFFEI, Rossana;MARTINELLI, Silvia;FIORCARI, STEFANIA;CASTELLI, Ilaria;COLUCCIO, Valeria;TORELLI, Giuseppe;MARASCA, Roberto
2010

Abstract

The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive of reduced TTFT (P < .001) and overall survival (P = .002). Multivariate analysis confirmed that high Ang2 was an independent prognosticator for TTFT (hazard ratio = 1.739; 95% confidence interval, 1.059-2.857; P = .029). Significant associations were found between high Ang2 and advanced Binet stages (P < .001), high beta(2)-microglobulin (P < .001), unmutated variable region of immunoglobulin heavy chain gene status (P < .001), high CD38 and zeta-chain-associated protein kinase 70 expression (P < .001 and P = .003), and intermediate/high cytogenetic risk (P = .005). Moreover, Ang2 added prognostic power to other conventional prognosticators and helped to refine prognosis among CLL subsets with both high and low vascular endothelial growth factor plasma levels. Ang2 plasma level may be a useful independent prognosticator for CLL.
116
584
592
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia / Maffei, Rossana; Martinelli, Silvia; Santachiara, R; Rossi, D; Guarnotta, C; Sozzi, E; Zucchetto, A; Rigolin, Gm; Fiorcari, Stefania; Castelli, Ilaria; Fontana, M; Coluccio, Valeria; Leonardi, G; Zucchini, P; Tripodo, C; Cuneo, A; Gattei, V; Del Poeta, G; Forconi, F; Gaidano, G; Torelli, Giuseppe; Marasca, Roberto. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 116:(2010), pp. 584-592. [10.1182/blood-2009-11-252494]
Maffei, Rossana; Martinelli, Silvia; Santachiara, R; Rossi, D; Guarnotta, C; Sozzi, E; Zucchetto, A; Rigolin, Gm; Fiorcari, Stefania; Castelli, Ilaria; Fontana, M; Coluccio, Valeria; Leonardi, G; Zucchini, P; Tripodo, C; Cuneo, A; Gattei, V; Del Poeta, G; Forconi, F; Gaidano, G; Torelli, Giuseppe; Marasca, Roberto
File in questo prodotto:
File Dimensione Formato  
maffei_Blood_2010 (Ang2 plasma).pdf

non disponibili

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 347.49 kB
Formato Adobe PDF
347.49 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/644218
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 45
social impact